Local Treatment Strategies in Renal Cell Carcinoma: Current Evidence and Future Directions

Abstract

The role of local treatment in renal cell carcinoma has been substantially refined in recent years. In localized disease, partial nephrectomy remains the standard treatment because it offers durable oncologic control, complete pathological assessment, and nephron preservation. With the development of cryoablation, radiofrequency ablation, microwave ablation, and stereotactic body radiotherapy, non-surgical local therapies have become important options for selected patients. Percutaneous ablation is best supported in small and technically accessible tumors, whereas stereotactic body radiotherapy provides a noninvasive alternative for patients unsuitable for surgery or invasive procedures. In metastatic renal cell carcinoma, cytoreductive nephrectomy has shifted from a routine upfront strategy to a selective intervention determined by patient selection and treatment sequencing. In oligometastatic and oligoprogressive disease, metastasis-directed local therapy may delay systemic treatment initiation, maintain the benefit of ongoing systemic therapy, and prolong disease control. Overall, local treatment for renal cell carcinoma has moved from isolated technical application toward stage-specific and precision-based integration. Future studies should further clarify indication boundaries, patient selection, treatment timing, long-term renal outcomes, and prospective comparative evidence.